Upper and lower limits in the renal clearance of acetylmesalazine in humans: Indications for renal acetylation of mesalazine

Clinical Drug Investigation

Volumn 21, Issue 2, 2001, Pages 147-156

  Vree, Tom B ^a   Dammers, Erik ^b   Exler, Peter S ^c   Sörgel, Fritz ^d   Bondesen, Stig ^e   Maes, Robert A A ^f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DADA Consultancy   (Netherlands)

^c Disphar International   (Netherlands)

^d Institute for Biomedical and Pharmaceutical Research   (Netherlands)

^e Frederiksberg Hospital   (Netherlands)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; MESALAZINE; MESALAZINE Y 500;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

EID: 0035096077     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121020-00007     Document Type: Article

References (41)

1. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid
2. Oral delayed-release mesalazine. A review of its use in ulcerative colitis and Crohn's disease
3. Gastro-intestinal agents
4. Pharmacokinetics of mesalazine from controlled-release capsules in man
5. Pharmacokinetics of a 5-aminosalicylic acid enteric coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers
6. Pharmacokinetics of mesalazine in man following administration of intravenous bolus and per os slow-release formulation
7. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease
8. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease
9. Metabolism and urinary excretion of mesalazine in healthy volunteers given intravenously or released for absorption at different sites in the gastro-intestinal tract
10. Saturable active tubular reabsorption in the renal clearance of mesalazine in human volunteers
11. Determination of the pK values of 5-aminosalicylic acid and N-acetylsalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites
12. Liver and gut acetylation of mesalazine in healthy volunteers
13. Kinetics of 5-aminosalicylic acid after jejunal installation in man
14. Availability of mesalazine from enemas and suppositories during steady state conditions
15. Mono and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in 24 healthy male volunteers controlled by the time of defecation before dosing
16. Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability
17. Steady-state pharmacokinetics of enteric coated 5-aminosalicylic acid tablets in healthy volunteers and in patients with Chrohn's disease or ulcerative colitis
18. Bioavailability of single and multiple doses of a new oral formulation of 5-asa in patients with inflammatory bowel disease and healthy volunteers
19. 4-acetyl metabolites of sulphasomidine and sulphadimethoxine in the dog
20. Saturable urinary excretion kinetics of famotidine in the dog
21. A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog
22. Pharmacokinetics of sulphamethoxazole in man: Effects of urinary pH and urine flow on metabolism and renal excretion of sulphamethoxazole and its metabolite Na-acetylsulphamethoxazole
23. The influence of urine flow on renal clearance of creatinine In patients with normal and impaired kidney function
24. 4-acetylsulphamethoxazole in patients with impaired kidney function
25. Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency
26. Dosage adjustments for ceftazidime in patients with impaired renal function
27. 1-glucuronidation and Na-acetylation of sulfa-6-monomethoxine in humans
28. Renal clearance
29. Renal handling of organic anions and cations and renal excretion of uric acid
30. Renal drug metabolism
31. Contribution of the human kidney to the metabolic clearance of drugs
32. Drag interactions at the renal level. Implications for drug development
33. Clearance of an oral delayed-release mesalazine preparation (Salofalk) by haemodialysis-pharmacokinetic profile of mesalazine related to effect of dialysis
34. Drug-induced changes in renal hippurate clearance as a measure of renal blood flow
35. Intrarenal distribution of blood flow
36. Normal physiology of the cardiovascular system
37. 5-Aminosalicylic acid in the treatment of inflammatory bowel disease
38. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man
39. Nephrotoxic lesions from 5-aminosallcylic acid
40. Comparative cytotoxicity of 5-aminosalicylic acid (mesalazine) and related compounds in different cell lines
41. Prospective study of the effect of 5-aminosalicylic acid (mesalazine) on renal function in inflammatory bowel disease